Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I

Journal of Inherited Metabolic Disease

Volumn 29, Issue 1, 2006, Pages 230-231

  Anbu, A T ^a   Mercer, J ^a   Wraith, J Ed ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LARONIDASE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG INFUSION; ENZYME REPLACEMENT; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; GENERAL CONDITION DETERIORATION; HUMAN; HURLER SYNDROME; PATIENT ASSESSMENT; PREDICTION; PREGNANCY; TREATMENT CONTRAINDICATION; TREATMENT WITHDRAWAL; VAGINAL DELIVERY; WALKING;

ADULT; FEMALE; HUMANS; IDURONIDASE; MUCOPOLYSACCHARIDOSIS I; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RECOMBINANT PROTEINS;

EID: 33645670132     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-006-0237-8     Document Type: Article

References (3)

1. Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al (2004) Pregnancies in Gaucher disease: A 5-year study. Am J Obstet Gynecol 190: 435-441.
2. Kakkis ED, Muenzer J, Tiller GE, et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182-188.
3. Wraith JE, Clarke LA, Beck M, et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: A randomised, double-Blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr 144: 581-588.